Outsourcing growth is predicted across all sponsor groups
Vice President of Market Research at Industry Standard Research Kate Hammeke discusses outsourcing trends from the results of a recent oral dosage survey with Life Science Leader.
In fact, across all sponsor groups, respondents predict increases in the proportion of oral-dose manufacturing that is outsourced. For clinical trial manufacturing, the increase averaged 6 percentage points, climbing from 54 percent to 60 percent outsourced, and for commercial manufacturing, the increase averaged 8 percentage points, rising from 57 percent to 65 percent outsourced.
Read more at Life Science Leader, and check out our 2019 Oral Dosage Forms Market Overview and Outlook (3rd Edition) to discover what outsourcing decision-makers at sponsor organizations think the oral dose market will look like in five years.